TrialDiabetes, obesity & metabolism2020

Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes.

Amalia Gastaldelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.